Uni-Bio Science Group

Uni-Bio Science Group EBITDA per Employee

The EBITDA per Employee of Uni-Bio Science Group (690.HK) as of Oct 20, 2026 is 270,105.88 HKD. In the previous year, EBITDA per Employee was 230,294.12 HKD — a change of 17.29% (higher).

EBITDA per Employee

270,105.88HKD

YoY

17.29%

Last updated:

EBITDA per Employee of Uni-Bio Science Group is 2024 270,105.88 HKD. EBITDA per Employee of Uni-Bio Science Group was 2023 230,294.12 HKD. It decreases by 17.29% higher compared to the previous year.

The Uni-Bio Science Group EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2017
-215,944.12 HKD
Jan 1, 2018
-334,011.76 HKD
Jan 1, 2019
-137,676.47 HKD
Jan 1, 2020
-82,957.35 HKD
Jan 1, 2021
10,470.59 HKD
Jan 1, 2022
146,917.65 HKD
Jan 1, 2023
230,294.12 HKD
Jan 1, 2024
270,105.88 HKD
The Uni-Bio Science Group EBITDA per Employee history
YEAREBITDA per EmployeeYoY
270,105.88HKD+17.29%
230,294.12HKD+56.75%
146,917.65HKD+1,303.15%
10,470.59HKD-112.62%
-82,957.35HKD-39.74%
-137,676.47HKD-58.78%
-334,011.76HKD+54.68%
-215,944.12HKD+42.64%
-151,391.18HKD-10.81%
-169,738.24HKD+27.13%
-133,514.71HKD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Uni-Bio Science Group Stock analysis

What does Uni-Bio Science Group do? Uni-Bio Science Group Ltd, listed on the Hong Kong Stock Exchange under ticker 690.HK with ISIN KYG9198H1406, operates in the Health Care sector within the Biotechnology industry. The company, which completed its IPO on November 12, 2001, employs 340 full-time staff. Uni-Bio Science Group functions through four business segments. The In-house Chemical Pharmaceutical Products segment focuses on manufacturing and selling proprietary chemical pharmaceutical products, including the product named Pinapu. The In-house Biological Pharmaceutical Products segment handles the production and distribution of biological pharmaceutical products such as GeneTime and GeneSoft. The In-house Biological Pipeline segment is dedicated to advancing the industrialization of its biological pipeline, featuring products like Uni-E4 and Uni-PTH. The Third-party Pharmaceutical Products segment manages the sales of pharmaceutical products from external suppliers. The company's headquarters location is not publicly specified, and its official website is www.uni-bioscience.com. Uni-Bio Science Group's business model integrates in-house development with third-party product distribution, targeting both chemical and biological pharmaceutical markets. The company's operational structure reflects a diversified approach to pharmaceutical research, development, and commercialization, though specific details about its research pipeline, market reach, or financial performance are not provided in the available information. Uni-Bio Science Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Uni-Bio Science Group stock

EBITDA per Employee of Uni-Bio Science Group is 270,105.88 HKD in 2024.

EBITDA per Employee of Uni-Bio Science Group changed from 230,294.12 HKD to 270,105.88 HKD, representing a 17.29% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Uni-Bio Science Group since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's HKD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Uni-Bio Science Group historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Uni-Bio Science Group

All Key Metrics — Uni-Bio Science Group